Matt Abernethy - 04 Mar 2026 Form 4 Insider Report for NEUROCRINE BIOSCIENCES INC (NBIX)

Reporting relationship: Chief Financial Officer
Issuer ticker: NBIX
Reported as of: 04 Mar 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 05 Mar 2026, 18:18:36 UTC
Prior SEC filing: 17 Feb 2026
Next SEC filing: 15 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Darin Lippoldt, Attorney-in-Fact

Key filing fact

Matt Abernethy filed Form 4 for NEUROCRINE BIOSCIENCES INC (NBIX) on 05 Mar 2026.

Key facts

This page summarizes Matt Abernethy's Form 4 filing for NEUROCRINE BIOSCIENCES INC (NBIX).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 05 Mar 2026, 18:18.

Change

Previous filing in this sequence was filed on 17 Feb 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001724097 Primary reporting owner

ABERNETHY MATT

Relationship: Chief Financial Officer
Address: 6027 EDGEWOOD BEND CT., SAN DIEGO
Signature: /s/ Darin Lippoldt, Attorney-in-Fact
Signature date: 05 Mar 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

NBIX transaction

Common Stock

Gift

Transaction value
Shares: -2,249
Change %: -5%
Price: $0.000000^*
Shares after: 42,808
Date: 04 Mar 2026
Ownership: Direct
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

This transaction represents a gift/charitable contribution effective March 4, 2026. This is not a market transaction, thus no price has been reported. No value was received for the gifted shares.

Footnote F2

Includes an aggregate of 176 shares purchased on February 27, 2026 from the Neurocrine Biosciences, Inc. 2018 Employee Stock Purchase Plan.